In the pipeline from Derek Lowe – Page 2
-
OpinionAlzheimer’s, amyloid and abandoned antibodies
Biogen’s aducanumab is stumbling into obscurity. Where does that leave the amyloid hypothesis?
-
OpinionCatalogues of complexity
The tangled web of fine chemicals supply frequently throws up surprises
-
OpinionExit strategy
Overcoming a major setback showed Derek Lowe could make it through graduate school
-
OpinionA spanner in the works
Most drugs work by breaking or stopping something, rather than by making something faster or better
-
OpinionScents and sentimentality
Deprived of familiar lab odours, Derek Lowe indulges in some nasal nostalgia
-
OpinionThe law of conservation of data
AI and machine learning are useful and powerful, but they need high quality data inputs that aren’t available yet for drug discovery
-
OpinionReverse combustion is preparing for takeoff
Where burning hydrocarbons is unavoidable, creating them from atmospheric carbon is a promising option
-
OpinionAll work and no play
Is the long-hours culture of academic organic chemistry laboratories finally changing?
-
OpinionWhere are the Covid-19 drugs?
Small molecules appear to be lagging behind development of vaccine and antibody treatments
-
OpinionThe price of failure
Drug market structures and high R&D failure rates can tempt companies into bad pricing behaviour
-
OpinionPutting combustion into reverse
Unburning carbon dioxide economically and at scale is a tough problem, but potentially world-changing
-
OpinionOpening up a cellular black box
Working out how biomolecular condensates work may reveal a lot about the success or failure of different drugs
-
OpinionThe side effects of being unique
Even the largest clinical trials won’t capture all possible bad reactions to a drug – we need pharmacovigilance
-
OpinionA powerful blow against misconduct
Supporting whistleblowers is vital for detecting and preventing bad behaviour
-
OpinionHow the pandemic might change drug research
Derek Lowe muses on some positive lessons learned
-
OpinionA rough guide to pharma partnership deals
Coronavirus vaccines are driving unusual collaborations with a range of benefits
-
OpinionRuling out the rule of five
Simple calculations for clinical trial success failed to find a winning formula
-
OpinionStirring in my sleep
Cut off from the lab after 40 years, Derek Lowe returns to the bench in his dreams
-
OpinionThe ins and outs of vaccine trials
Derek Lowe lays out how the trials work, and why they get paused and restarted
-
OpinionThe Nobel prize that got binned
Ferrocene is a classic example of a discovery that was dismissed as a failed experiment